Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2014

Open Access 01-01-2014 | Original Article

Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations

Authors: James E. Wraith, Frédéric Sedel, Mercèdes Pineda, Frits A. Wijburg, Christian J. Hendriksz, Michael Fahey, Mark Walterfang, Marc C. Patterson, Harbajan Chadha-Boreham, Stefan A. Kolb

Published in: Journal of Inherited Metabolic Disease | Issue 1/2014

Login to get access

Abstract

Objective

The Suspicion Index (SI) screening tool was developed to identify patients suspected of having Niemann-Pick disease type C (NP-C). The SI provides a risk prediction score (RPS) based on NP-C manifestations within and across domains (visceral, neurological, and psychiatric). The aim of these subanalyses was to further examine the discriminatory power of the SI by age and manifestation–associations by NP-C suspicion-level and leading manifestations.

Methods

The original retrospectively collected data were split into three patient age groups, where NP-C-positive cases were >16 years (n = 30), 4–16 years (n = 18), and <4 years (n = 23), and patients’ RPS were analyzed by logistic regression. Co-occurrence of manifestations within groups of suspicion level (low, medium, high) and leading manifestations (presence/absence of ataxia, cognitive decline, psychosis, and splenomegaly) were analyzed descriptively.

Results

NP-C-positive cases versus controls showed strong discriminatory power of RPS. Area under the receiver operating characteristic curve was 0.964 (>16 years) and 0.981 (4–16 years) but weaker 0.562 for infants (<4 years). Patients with RPS <70 were characterized by a lack of psychiatric manifestations and low levels of neurological involvement, suggestive of a preneurological phase of the disease. In patients >4 years, prominent leading manifestation–associations were ataxia with dystonia, dysarthria/dysphagia, and cognitive decline. Psychosis was associated with dysarthria/dysphagia but also with cognitive decline and treatment-resistant psychiatric symptoms.

Conclusions

The SI tool maintains strong discriminatory power in patients >4 years but is not as useful for infants <4 years. The SI is also informative regarding the association and co-occurrence of manifestations in patients with NP-C.
Literature
go back to reference Chien YH, Peng SF, Yang CC, et al. (2013) Long-term efficacy of miglustat in paediatriC-patients with Niemann-Pick disease type C. J Inherit Metab Dis. 36:129–137 Chien YH, Peng SF, Yang CC, et al. (2013) Long-term efficacy of miglustat in paediatriC-patients with Niemann-Pick disease type C. J Inherit Metab Dis. 36:129–137
go back to reference Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, NP-C Guidelines Working Group (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106:330–344PubMedCrossRef Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, NP-C Guidelines Working Group (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106:330–344PubMedCrossRef
go back to reference Pineda M, Perez-Poyato MS, O’Callaghan M et al (2010) Clinical experience with miglustat therapy in pediatriC-patients with Niemann-Pick disease type C: a case series. Mol Genet Metab 99:358–366PubMedCrossRef Pineda M, Perez-Poyato MS, O’Callaghan M et al (2010) Clinical experience with miglustat therapy in pediatriC-patients with Niemann-Pick disease type C: a case series. Mol Genet Metab 99:358–366PubMedCrossRef
go back to reference Wijburg FA, Sedel F, Pineda M et al (2012) Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C. Neurology 78:1560–1567PubMedCrossRef Wijburg FA, Sedel F, Pineda M et al (2012) Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C. Neurology 78:1560–1567PubMedCrossRef
go back to reference Wraith JE, Imrie J (2009) New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag 5:877–887PubMedCentralPubMedCrossRef Wraith JE, Imrie J (2009) New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag 5:877–887PubMedCentralPubMedCrossRef
go back to reference Wraith JE, Baumgartner MR, Bembi B et al (2009) Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98:152–165PubMedCrossRef Wraith JE, Baumgartner MR, Bembi B et al (2009) Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98:152–165PubMedCrossRef
go back to reference Wraith JE, Vecchio D, Jacklin E et al (2010) Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 99:351–357PubMedCrossRef Wraith JE, Vecchio D, Jacklin E et al (2010) Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 99:351–357PubMedCrossRef
Metadata
Title
Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations
Authors
James E. Wraith
Frédéric Sedel
Mercèdes Pineda
Frits A. Wijburg
Christian J. Hendriksz
Michael Fahey
Mark Walterfang
Marc C. Patterson
Harbajan Chadha-Boreham
Stefan A. Kolb
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 1/2014
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-013-9626-y

Other articles of this Issue 1/2014

Journal of Inherited Metabolic Disease 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.